SHINE Technologies announced recently that it is entering into a supply agreement with GlyTherix Ltd, an Australian targeted-radiotherapy company specializing in developing antibody radiopharmaceuticals for solid tumors.

According to a release, the partnership will help advance targeted radiotherapy in aggressive and invasive cancers.

“Our partnership with GlyTherix, a true pioneer in targeted radiotherapy, represents an important step in advancing next-generation cancer treatments,” SHINE CEO and Founder Greg Piefer said in a statement. “GlyTherix’s innovative approach has the potential to transform cancer care for patients with some of the most challenging solid tumors. By providing a reliable supply of high-quality Ilumira, we’re proud to support their groundbreaking work that could offer new hope to patients with limited treatment options.”

SHINE will supply non-carrier added lutetium-177 chloride for use in GlyTherix’s clinical trials with a particular focus on the expansive U.S. market.